Table 4.
Virus‐encoded DUBs in host innate antiviral immunity.
Virus family | Virus | Virus‐encoded DUB | Host Target | Linkage | Rationale |
---|---|---|---|---|---|
RNA virus | |||||
Coronaviridae/ alphacoronaviruses | Human coronavirus NL63 | PLP2 | RIG‐I, TBK1, IRF3, STING | Lys48/63 | Negatively regulate antiviral defenses by disrupting the STING‐mediated IFN induction[ 554 ] |
Mouse hepatitis virus | MHV PLP2 | IRF3, TBK1 | NA | Negatively regulate type I IFN signaling[ 555 , 556 ] | |
Porcine epidemic diarrhea virus | PEDV PLP2 | RIG‐I, STING | NA | Interfere with the RIG‐I‐ and STING‐mediated signaling[ 557 ] | |
Coronaviridae/ betacoronaviruses | SARS‐coronavirus (2) | SARS‐CoV PLpro | RIG‐I, TRAF3, STING, TBK1, IRF3, MDA5 | Lys48/63, ISG15 | Negatively regulate IRF3 activation.[ 558 , 559 ] Antagonize ISG15‐dependent activation of MDA5[ 560 ] |
MERS‐ coronavirus | MERS‐CoV PLpro | IRF3 | Lys48/63, ISG15 | Negatively regulate IRF3 activation[ 561 , 562 ] | |
Arteriviridae | Porcine reproductive and respiratory syndrome virus | PRRSV PLP2 | RIG‐I | Lys6/11/27/29/33/48/63 | Inhibits RIG‐I‐mediated IFN signaling[ 246 ] |
IκBα | Inhibit NF‐κB activation[ 563 ] | ||||
Equine arteritis virus | EAV PLP2 | RIG‐I | NA | Inhibits RIG‐I‐mediated IFN signaling[ 246 ] | |
Bunyaviridae/ nairoviruses | Crimean‐Congo hemorrhagic fever virus | CCHFV OTU | MDA5, RIG‐I | Lys6/11/48/63, ISG15 | Inactivate RLR‐mediated innate immune signaling[ 246 ] |
Arteriviridae | Simian hemorrhagic fever virus | SHFV PLP2 | RIG‐I | NA | Inhibits RIG‐I‐mediated IFN signaling[ 246 ] |
Lactate dehydrogenase‐elevating virus | LDV PLP2 | RIG‐I | NA | Inhibits RIG‐I‐mediated IFN signaling[ 246 ] | |
Picornaviridae | Dugbe virus | DUGV OTU | NA | Lys48/63 | Negatively regulate type I IFN signaling[ 564 ] |
Foot‐and‐mouth disease virus | FMDV Lbpro | RIG‐I, TBK1, TRAF3, TRAF6 | Lys48/63 | Negatively regulate type I IFN signaling[ 565 ] | |
Seneca valley viru | SVV 3Cpro | RIG‐I, TBK1, TRAF3 | NA | block IFN‐β induction[ 252 ] | |
DNA virus | |||||
Adenoviridae | Adenovirus | Adenain | Histone H2A | Lys48, ISG15 | Acquire an advantageous property by adenovirus[ 241 ] |
Herpesviridae/ alphaherpesviruses | Herpes simplex virus | UL36USP | TRAF3 | Lys48/63 | Deubiquitinate TRAF3 and prevent the recruitment of the downstream adaptor TBK1[ 566 ] |
IκBα | Lys48 | Restrict IκBα degradation and finally abrogate NF‐κB activation[ 567 ] | |||
STING | Lys48 | Inhibits induction of type I IFN[ 253 ] | |||
Herpesviridae/ betaherpesviruses | Human cytomegalovirus | pUL36USP | MLKL | Lys63 | Degrade MLKL and inhibit necroptosis[ 568 ] |
Herpesviridae/ gammaherpesviruses | Epstein‐Barr virus | BPLF1 | PCNA | Lys48/63 | Disrupt the cellular response to DNA damage[ 569 ] |
SQSTM1/p62 | Regulate selective autophagy, which may promote infection and the production of infectious virus[ 570 ] | ||||
Cullin | Benefit virus life cycle by inducing a replication‐permissive S‐phase‐like cellular environment[ 571 ] | ||||
TRAF6 | Deubiquitinate TRAF6 to inhibit NF‐κB signaling[ 572 ] | ||||
TRAF6, NEMO, IκBα | Deubiquitinate signaling intermediates in the TLR cascade to counteract innate anti‐viral immunity[ 255 ] | ||||
Kaposi's sarcoma‐associated herpesvirus | KSV ORF64 | RIG‐I | Lys48/63 | Suppresse RIG‐I‐mediated IFN signaling[ 573 ] | |
Herpesviridae | Hepatitis B virus | HBx | RIG‐I | Lys63 | Evade the induction of IFN and IFN‐induced antiviral effects[ 574 ] |
RIG‐I, TBK1, CARDIF, TRIF, NEMO, IKKi, IRF3 | Negatively regulate type I IFN production[ 575 ] |